The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - ASLAN Pharmaceuticals; eTheRNA Immunotherapies; Galecto
Leadership - ASLAN Pharmaceuticals; eTheRNA Immunotherapies; Galecto
Stock and Other Ownership Interests - ASLAN Pharmaceuticals
Patents, Royalties, Other Intellectual Property - ASLAN Pharmaceuticals
Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).
 
Milind M. Javle
Consulting or Advisory Role - incyte; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; Lilly
 
Masafumi Ikeda
Honoraria - Astellas Pharma; Bayer Yakuhin; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; MSD; Novartis; Ono Pharmaceutical; SERVIER; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Wei-Peng Yong
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Bristol-Myers Squibb; Ipsen; Novartis
Speakers' Bureau - Eisai; Lilly; Sanofi/Aventis; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Pfizer
 
Nicola McIntyre
Stock and Other Ownership Interests - GlaxoSmithKline
Consulting or Advisory Role - Achilles Therapeutics; ASLAN Pharmaceuticals; Evgen
Travel, Accommodations, Expenses - Achilles Therapeutics; ASLAN Pharmaceuticals
 
Bertil Lindmark
No Relationships to Disclose
 
Mark McHale
Employment - ASLAN Pharmaceuticals
Leadership - ASLAN Pharmaceuticals
Stock and Other Ownership Interests - ASLAN Pharmaceuticals
Patents, Royalties, Other Intellectual Property - ASLAN Pharmaceuticals
Travel, Accommodations, Expenses - ASLAN Pharmaceuticals